[Changes in IGFBP-3 in relation to administration of rGH to deficient children]

Area of Science:

• Pediatric Endocrinology
• Growth Hormone Therapy
• Biomarker Analysis

Background:

• Growth hormone deficiency (GHD) affects childhood development.
• Insulin-like growth factor-binding protein 3 (IGFBP3) is a key mediator of growth hormone action.
• Monitoring IGFBP3 levels can indicate treatment response in GHD patients.

Purpose of the Study:

• To evaluate serum IGFBP3 levels in children with GHD during and after recombinant human growth hormone (rGH) therapy.
• To determine the time course of IGFBP3 normalization post-treatment.

Main Methods:

• Serum samples were collected from 7 GHD children.
• IGFBP3 concentrations were measured before, at the end of, and 1, 2, 4, and 8 weeks after rGH therapy.
• Statistical analysis of IGFBP3 level changes over time.

Main Results:

• Serum IGFBP3 levels were assessed throughout the study period.
• IGFBP3 concentrations returned to pre-therapy baseline levels approximately 6 weeks after the cessation of rGH therapy.
• A delayed normalization of IGFBP3 was observed post-treatment.

Conclusions:

• Serum IGFBP3 normalization occurs with a delay after completing rGH therapy in children with GHD.
• A 6-week follow-up period is suggested for assessing IGFBP3 recovery post-therapy.
• IGFBP3 serves as a valuable biomarker for monitoring the long-term effects of rGH treatment.